Evidence map›Paper›PMID 26356563›Full record

ArticleOncotarget2015

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.

Xinyan Wu, Muhammad Saddiq Zahari, Binyun Ma, Ren Liu, Santosh Renuse, Nandini A Sahasrabuddhe, Lily Chen, Raghothama Chaerkady, Min-Sik Kim, Jun Zhong and 17 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. A FBXO7/EYA2-SCFMolecular cell · 2022
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Tumor reversion: a dream or a reality.Biomarker research · 2021
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 4 institutions in 3 countries.

Xinyan WuDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Muhammad Saddiq ZahariDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Binyun MaDepartment of Medicine, University of Southern California, Los Angeles, CA, USA.
Ren LiuDepartment of Medicine, University of Southern California, Los Angeles, CA, USA.
Santosh RenuseDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nandini A SahasrabuddheDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lily ChenDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Raghothama ChaerkadyDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Min-Sik KimDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jun ZhongDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Christine JelinekDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mustafa A BarbhuiyaDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pamela Leal-RojasDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yi YangDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Manoj Kumar KashyapDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Arivusudar MarimuthuDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Min LingDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mary Jo FacklerDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vanessa MerinoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zhen ZhangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Cynthia A ZahnowDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Edward GabrielsonDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vered StearnsDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Juan Carlos RoaAdvanced Center for Chronic Diseases (ACCDiS), Department of Pathology Pontificia Universidad Católica de Chile, Santiago, Chile.
Saraswati SukumarDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Parkash S GillDepartment of Medicine, University of Southern California, Los Angeles, CA, USA.
Akhilesh PandeyDepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of Southern California · USPontificia Universidad Católica de Chile · CL

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Proteome Characterization Center: A Genoproteomics Pipeline for Cance ResearchU24CA160036 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2011 to 2016
$10.7M
Networks, Pathways and Dynamics of Lysine ModificationU54GM103520 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BADER, JOEL S. · 2012 to 2013
$7.0M
NCI NIH HHS CA006973NCI NIH HHS P30 CA006973NCI NIH HHS U24 CA160036NCI NIH HHS U24CA160036NHLBI NIH HHS HHSN268201000032CNIGMS NIH HHS U54 GM103520NIGMS NIH HHS U54GM103520PHS HHS HHSN268201000032C
6 · The paper itself

Abstract

Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers are triple negative breast cancer (TNBC) and are often highly aggressive when compared to other subtypes of breast cancers. To better characterize the biology that underlies the TNBC phenotype, we profiled the phosphotyrosine proteome of a panel of twenty-six TNBC cell lines using quantitative high resolution Fourier transform mass spectrometry. A heterogeneous pattern of tyrosine kinase activation was observed based on 1,789 tyrosine-phosphorylated peptides identified from 969 proteins. One of the tyrosine kinases, AXL, was found to be activated in a majority of aggressive TNBC cell lines and was accompanied by a higher level of AXL expression. High levels of AXL expression are correlated with a significant decrease in patient survival. Treatment of cells bearing activated AXL with a humanized AXL antibody inhibited cell proliferation and migration in vitro, and tumor growth in mice. Overall, our global phosphoproteomic analysis provided new insights into the heterogeneity in the activation status of tyrosine kinase pathways in TNBCs. Our approach presents an effective means of identifying important novel biomarkers and targets for therapy such as AXL in TNBC.

Indexed as

ProteomicsSignal TransductionAnimalsAntineoplastic AgentsAxl Receptor Tyrosine KinaseBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationEnzyme ActivationFemaleFourier AnalysisHumansKaplan-Meier EstimateMass SpectrometryMice, Inbred NODAntineoplastic AgentsAxl Receptor Tyrosine KinaseBiomarkers, TumorPhosphotyrosineProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAXLkinaseprotein phosphorylationproteomicstriple negative breast cancer

Identifiers

PMID26356563
PMCPMC4745717
OpenAlexW2211064704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.